Danaher Gears Up to Post Q2 Earnings: What Lies Ahead for the Stock?

• click to rate

  Posted by Two Blokes Jul 18 - Filed in Stock - 2 views
  
  DHR's Q2 results are likely to reflect Life Sciences weakness, but strength in Biotechnology & Diagnostics units and Abcam acquisition add upside potential.